NVP-BEP800 (Synonyms: NVP-BEP800)

Competitive binding fluorescent polarization assay

Recombinant Hsp90β, TAMRA-radicicol, or various concentrations of NVP-BEP800 was added in assay buffer (50 mM TRIS pH 7.4, 5 mM MgCl2, 150 mM KCl and 0.1% CHAPS), mixed and incubated at room temperature for 30 ~ 45 mins prior to reading. The 2D-FIDA-based HTS assay based on confocal technologies monitored the decreased fluorescence polarization on displacement of the high affinity ligand TAMRA-radicicol from Hsp90β by NVP-BEP800. The concentration of NVP-BEP800 which inhibited Hsp90β by 50% was determined from the competition curve.

Cell lines

BT-474 cells

Preparation method

The solubility of this compound in DMSO is limited. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.

Reacting condition

50 ~ 500 nM; 24 hrs

Applications

In BT-474 cells, NVP-BEP800 concentration-dependently decreased phospho-Akt (Ser473) and ErbB2 levels. At the dose of 500 nM, phosphorylation of Akt at Ser473 was not detectable, and lower levels of Akt and ErbB2 were also detected.

Animal models

Mice bearing breast cancer BT-474 cell xenografts

Dosage form

15 or 30 mg/kg/day; p.o.

Applications

In mice bearing breast cancer BT-474 cell xenografts, NVP-BEP800 dose-dependently increased Hsp90-p23 complex dissociation and lowered the levels of steady-state ErbB2, phospho-Akt as well as phospho-S6. NVP-BEP800 induced 38% tumor regression at dose of 30 mg/kg/day and a T/C value of 36% at dose of 15 mg/kg/day.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Massey AJ, Schoepfer J, Brough PA, Brueggen J, Chène P, Drysdale MJ, Pfaar U, Radimerski T, Ruetz S, Schweitzer A, Wood M, Garcia-Echeverria C, Jensen MR. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther. 2010 Apr;9(4):906-19.